1.36

2.86% -0.04

Pre-market: 1.38 0.02 +1.47%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.36, with a volume of 2.40M. It is down -2.86% in the last 24 hours and up +9.68% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$1.40

Open:

$1.37

24h Volume:

2.40M

Relative Volume:

0.74

Market Cap:

$364.32M

Revenue:

$236.20M

Net Income/Loss:

$-5.35M

P/E Ratio:

-75.98

EPS:

-0.0179

Net Cash Flow:

$67.70M

1W Performance:

-8.72%

1M Performance:

+9.68%

6M Performance:

-50.90%

1Y Performance:

-33.33%

1-Day Range:

$1.33

$1.40

1-Week Range:

$1.33

$1.515

52-Week Range:

$1.14

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2024-11-07

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	1.36	364.32M	236.20M	-5.35M	67.70M	-0.0179
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

Mar 23, 2026

Is the options market predicting a spike in Akebia Therapeutics stock? - MSN

Mar 23, 2026

Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn

Mar 23, 2026

Mar 21, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 21, 2026

Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com

Mar 21, 2026

Mar 20, 2026

Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn

Mar 20, 2026

AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 20, 2026

Mar 19, 2026

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times

Mar 19, 2026

Mar 17, 2026

Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget

Mar 17, 2026

Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance

Mar 17, 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Mar 17, 2026

Mar 14, 2026

Akebia Q2 2025 Earnings Preview - MSN

Mar 14, 2026

Mar 12, 2026

AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 12, 2026

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus

Mar 12, 2026

Mar 10, 2026